Emerging Markets A Growth Pillar For Takeda
This article was originally published in PharmAsia News
Executive Summary
Japan's largest pharma company, Takeda, has revised its profit guidance for the current fiscal year on a mix of positive and negative factors, and logged a strong performance in emerging markets despite some weakness elsewhere.